Date:12/29/2009

letter of transmittal and related documents to Trimeris stockholders. Trimeris has filed with the SEC and mailed to Trimeris stockholders, a solicitation/recommendation statement on Schedule 14D-9, as amended. These documents contain important information about the tender offer and the merger and stockholders of Trimeris are urged to read them carefully in their entirety, as well as any amendments or supplements to these documents, including the amendment to the Schedule TO filed with the SEC on December 29, 2009 regarding the termination of the tender offer. These materials were sent free of charge to all stockholders of Trimeris. Investors and security holders are also able to obtain free copies of the tender offer statement, the tender offer solicitation/recommendation statement and other documents filed with the SEC by Arigene and Trimeris through the web site maintained by the SEC at www.sec.gov.

SOURCE Arigene Co., Ltd.

'/>"/>

SOURCE Arigene Co., Ltd. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related medicine technology :

1. Arigene Co., Ltd. Enters Into Amendment To Merger Agreement With Trimeris, Inc.
2. Vermillion Announces $43.05 Million Private Placement of Common Stock
3. ViVre Medical Announces $6,000,000 Gift
4. Soligenix Announces Publication of Positive Pre-Clinical Results with RiVax(TM), Its Vaccine Against Ricin Toxin
5. Maxygen, Inc. Announces Preliminary Results of Dutch Auction Tender Offer
6. Boston Scientific Announces Settlement of DOJ Investigation Relating to Post-Market Surveys Conducted By Guidant
7. Raptor Pharmaceutical Corp. Announces Closing of $7.5 Million Registered Direct Offering
8. MiMedx Group Announces Launch of its Paradis Vaso Shield(TM) Device
9. Alimera Announces Positive Results From the Two Phase 3 FAME(TM) Trials of Iluvien(R) in Patients With Diabetic Macular Edema
10. China Medicine Announces Changes to Management Team
11. PDI Announces New Pharmaceutical Services Business Win With a Top 5 Pharmaceutical Company